Allergan’s migraine results closer to US filing

Allergan has reported a positive readout from its second trial for the treatment of migraines.
The results show a significant reduction in migraine pain two hours after a 50mg dose of ubrogepant was administered.

A lower dosage of 25mg also showed a reduction in pain, but unlike the higher dosage, it wasn’t sufficient, with other symptoms including light sensitivity, loud sounds or nausea.
Allergan is preparing to file the drug next year in the US.

Analyst David Maris at Wells Fargo said Allergan’s new drug seems to offer triptan-like pain relief with an improved safety profile, and could be an option for an estimated four million people in the US with migraine who do not respond to or cannot tolerate triptan drugs, with blockbuster sales potential